Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M. Forde, Drew M. Pardoll, Jamie E. Chaft et al.|New England Journal of Medicine|2018Cited by 2.1k
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancerSteven D. Leach, Taha Merghoub, Vinod P. Balachandran et al.|Nature|2017Cited by 1.2k
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancersJustina X. Caushi, Kellie N. Smith, Taha Merghoub et al.|Nature|2021Cited by 546
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumoursRoberta Zappasodi, Taha Merghoub|Nature|2021Cited by 389
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint InhibitionBarzin Y. Nabet, Maximilian Diehn, Mohammad Shahrokh Esfahani et al.|Cell|2020Cited by 360